Malaysia's E-cigarette Legalization Still in Question

Aug.09.2022
Malaysia's E-cigarette Legalization Still in Question
The legalization of e-cigarettes sales in Malaysia faces challenges as the proposed "Generation End" anti-smoking bill is under review.

The main advocacy organization in the region, MOVE (Malaysia Vape Entity), has stated that the legalization of electronic cigarette sales in Malaysia still faces challenges, following unexpected turns prior to the Parliamentary elections.


Samsul Kamal Ariffin, the CEO of MOVE, has announced that the proposed "end intergenerational smoking" bill has been referred to a special committee in parliament for further scrutiny, which he considers to be positive news.


We are concerned that electronic cigarettes will be included in this anti-smoking bill, which will result in strict regulations and criminalization of consumers and retailers. Members of the specialized committee now have the opportunity to remove electronic cigarettes and non-combustible products from the legislation and treat them as tools for harm reduction in a completely different manner," said Mr. Alifin.


The date for Malaysia's general election is yet to be confirmed. However, if the next parliamentary session is held earlier, a select committee will take action to prepare a statement on its proposed amendments. MOVE will have a representative serving as a member of this special committee.


Similar to current legislation in New Zealand, Malaysia's proposed "intergenerational end" bill seeks to ban the sale of cigarettes and tobacco products to anyone born after 2007. However, unlike New Zealand, Malaysia's Health Minister also suggests adding electronic cigarette products to the intergenerational ban.


If Malaysia aims to reduce its overall smoking rate to below 5% by 2040, a ban on electronic cigarettes would not be able to achieve that goal. New Zealand has a smoking rate that is less than half of ours because they have become increasingly strict on smoking while only regulating the retail channels of adult e-cigarette products. New Zealand will likely achieve a smoke-free status at least a generation earlier than us because their approach to smoking and e-cigarette use is vastly different. If we want to save lives, Malaysia must do the same," he said.


In April, advocates for tobacco harm reduction (THR) were encouraged when regulations for electronic cigarette devices were announced to take effect on August 3rd. They had been lobbying for this to happen before the legalization of electronic cigarette sales, as have other THR supporters for many years.


We were concerned when the Health Minister proposed the "legacy of generations" bill on August 2nd and intended to pass it before parliament adjourned. Fortunately, enough members of parliament fought back, and the select committee or the next parliament can now regulate e-cigarettes through separate legislation. This is what needs to happen, and I believe it will.


As evidenced by 70 countries, the THR method is effective. Banning e-cigarettes will only harm smokers. Regulating e-cigarettes will provide a viable and less harmful alternative for smokers, not to mention much-needed tax revenue for Malaysia," said Mr. Alifin.


For the past decade, it has been a black market for electronic cigarette users in Malaysia, with unapproved products being untaxed and no safety guarantees for local consumers regarding product standards.


According to Mr. Alifin, providing a feasible, safe, and legal way for the 21% of Malaysians who smoke to improve their health and well-being is crucial. Electronic cigarettes are believed to be 95% less harmful than combustible tobacco. Making safer nicotine products legally available is the only way to significantly reduce Malaysia's unnecessary high smoking rates and save tens of thousands of lives each year.


The Asia Pacific Advocates for Tobacco Harm Reduction Alliance (CAPHRA) has endorsed the legalization and regulation of e-cigarette sales in Malaysia, believing it will lead to a significant reduction in smoking rates.


MOVE continues to work with political figures and health officials in Malaysia to provide them with necessary information and support to effectively tackle the country's smoking epidemic. CAPHRA believes that the unsuccessful ban on e-cigarettes in Malaysia will be lifted in the next few months and there will be no turning back, said Nancy Lucas, CAPHRA's Executive Coordinator.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS. 2FIRSTS also cannot confirm the truthfulness or accuracy of the content of the article. The compilation of this article is solely for industry exchange and research purposes.


Due to limitations in translation proficiency, the translated article may not fully capture the original author's intended meaning. Therefore, please refer to the original text for accuracy.


2FIRSTS aligns completely with the stance and position of the Chinese government on any domestic, cross-strait, or foreign related issues.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24